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Abstract 
BACKGROUND: The cannabinoid receptor 2 (CB2) plays a pleiotropic role in the innate immunity and is 
considered a crucial mediator of liver disease. Cannabinoid CB2 receptor activation has been reported to 
attenuate liver fibrosis in CCl4 exposed mice and also plays a potential role in liver regeneration in a mouse 
model of I/R and protection against alcohol-induced liver injury.  
AIM: In this study, we investigated the impact of CB2 receptors on the antifibrotic and regenerative process 
associated with cholestatic liver injury.  
METHODS: Twenty-six rats had bile duct ligation co-treated with silymarin and AM1241 for 3 consecutive weeks. 
Serum hepatotoxicity markers were determined, and histopathological evaluation was performed. 
RESULTS: Following bile duct ligation (BDL) for 3 weeks, there was increased aminotransferase levels, marked 
inflammatory infiltration and hepatocyte apoptosis with induced oxidative stress, as reflected by increased lipid 
peroxidation. Conversely, following treatment with the CB2 agonist, AM-1241, BDL rats displayed a reduction in 
liver injury and attenuation of fibrosis as reflected by expression of hydroxyproline and α-smooth muscle actin. 
AM1241 treatment also significantly attenuated lipid peroxidation end-products, p53-dependent apoptosis and 
also attenuated inflammatory process by stimulating IL-10 production. Moreover, AM1241 treated rats were 
associated with significant expression of hepatic progenitor/oval cell markers. 
CONCLUSION: In conclusion, this study points out that CB2 receptors reduce liver injury and promote liver 
regeneration via distinct mechanisms including IL-10 dependent inhibition of inflammation, reduction of p53-reliant 
apoptosis and through stimulation of oval/progenitor cells. These results suggest that CB2 agonists display potent 
hepatoregenrative properties, in addition to their antifibrogenic effects. 
 
 
Introduction 
 
Liver fibrosis is a clinical condition, 
characterised by an accumulation of extracellular 
matrix proteins as a result of prolonged liver injury. At 
the same time, there is a continued stimulus for 
regeneration, prompting further mutilation of the 
hepatic architecture and vascular structures. If left 
untreated, fibrosis can progress into cirrhosis, 
hepatocellular carcinoma and liver failure. The 
incidence of liver fibrosis has been increased 
significantly in recent years [1]. Until now, patients 
suffering from hepatic fibrosis are treated in such a 
way to compensate such impaired hepatic functions. 
For quite a long time, liver fibrosis had been 
considered irreversible. 
Nonetheless, there is aggregating clinical and 
experimental data to propose otherwise. Histological 
evaluation of biopsies from patients with chronic liver 
injury and animal models of fibrosis demonstrates that 
fibrosis is a dynamic, bi-directional process. Thus 
remodelling of fibrous scar and recovery is 
conceivable [2]. 
There is growing evidence suggesting that 
endocannabinoids may regulate the pathophysiology 
of liver diseases and plays an important role in 
apoptosis, tissue homeostasis, cell differentiation and 
proliferation. Under normal conditions, the 
endocannabinoid system is quite inactive and CB1, 
and CB2 receptors are barely expressed, partially 
because they are not expressed in hepatocytes. 
However, many studies have demonstrated the up-
regulation of the expression of CB1 and CB2 
receptors in hepatic myofibroblasts and vascular 
endothelial cells, as well as the increased 
concentration of endocannabinoids, especially 
anandamide, in the liver in the course of chronic 
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progressive liver diseases [3]. CB1 receptors possess 
a pro-fibrogenic effect in the liver and have also been 
implicated in the pathogenesis of alcoholic and 
nonalcoholic fatty liver diseases [4], [5]. On the other 
hand, CB2 receptors protect the liver against the 
development of fibrosis in CCl4 exposed mice [6], [7] 
and also play a potential role in liver regeneration in 
mouse model I/R [8] and protection against alcohol-
induced liver injury.  
Although, CB2 receptor agonists were 
reported to afford hepatic protection only in a model of 
I/R and CCl4 [9], [10]. In this study, we have 
investigated the effects of a CB2 receptor agonist 
(AM-1241) on a well-established rat model of 
cholestasis-induced fibrosis induced by three weeks’ 
ligation of bile duct [11], [12], [13]. We have also 
explored the effects of AM-1241 on the production of 
the key immune-regulatory cytokine, IL-10 that affect 
hepatic inflammatory cells and also on oxidative lipid 
peroxidation and hepatocyte p53- dependent 
apoptosis. Besides, we have also explored the effects 
of CB2 receptors on regenerative effect through 
stimulation of liver progenitor (oval) cells. The latter, in 
turn, caused further attenuation of liver injury with 
replacement with healthy hepatocytes. Our findings 
strengthen the potential of CB2 receptors for the 
treatment of BDL injury and other fibrotic disorders. 
Results were compared to the effects of 
silymarin, a drug commonly used as liver support 
during the treatment of cirrhosis. Silymarin has a great 
activity against a wide range of animal models of 
hepatic injury due to its antioxidant activity and radical 
scavenging. Silymarin was also reported to exert anti-
inflammatory effects through the reduction of TNF-α 
[14].  
The aim of the study is to evaluate the 
hepatoprotective effects of the Cannabinoid 2 receptor 
agonist, AM-1241, on hepatic fibrosis induced by 
common bile duct ligation of adult rats and to 
investigate its anti-inflammatory, antioxidant and anti-
apoptotic potentials. 
 
 
Material and Methods 
 
Animals 
Twenty-four; Adult male Wistar albino rats, of 
approximately 180-220 g body weight, were obtained 
from the animal house colony, National Research 
Centre, Giza, Egypt. All animals were housed in metal 
cages in a well-ventilated environment at (22 ± 3°C, 
55 ± 5% humidity and 12h dark & light cycles) and 
were provided with a standard pellet diet (containing 
not less than 20% protein, 5% fiber, 3.5% fat, 6.5% 
ash and a vitamin mixture) and water ad libitum. All 
animal care and experimental procedures were 
approved by Ethical Committee of National research 
centre, Egypt (registration number: 16-036) and 
followed the ARRIVE (Animal Research: Reporting In-
Vivo Experiments) guidelines [15]. 
 
 
Material 
 
AM1241 was purchased from CaymanChem, 
Czech Republic. Silymarin was granted from CID, 
Egypt. Diethyl ether, Formaldehyde solution 34-38%, 
DMSO and PBS were obtained from Sigma, Egypt. 
Ketamine, Thylacine and Ceftriaxone have obtained 
from Egyptian companies; SIGMA TEC, ADWIA and 
EPICO respectively. 
 
General procedures 
Bile duct ligation (BDL) has been widely used 
for experimental induction of liver fibrosis in rats [16]. 
For this purpose, rats were anaesthetized with 
ketamine (50 mg/kg, i.p) and thylacine (5 mg/kg, i.p) 
[17] then the abdomen was shaved and disinfected. 
The common bile duct was exposed and twice ligated 
with 3-0 silk suture. Sham operation was performed 
by gently touching the bile duct without ligation. The 
abdomen was closed in layers. The animals were 
allowed to recover on a heating pad. Rats were 
injected with ceftriaxone (30 mg/kg, im) 30 minutes 
before surgery for prophylaxis against infection [18]. 
The experimenters were blinded to the treatments 
given to the animals and the biochemical and 
histological analyses and the data analyses. 
 
Experimental design 
The day after the operation, animals were 
randomly divided into four groups of six rats each and 
treated for three consecutive weeks as follows: The 
first group was sham-operated and served as the non-
treated control, receiving vehicle only. The second 
group had a bile duct ligation then it was given the 
vehicle (BPS/DMSO solution in a ratio of 2:1), 
intraperitoneally. The third group also had bile duct 
ligation then was given silymarin daily in a dose of 100 
mg/kg dissolved in the vehicle, intraperitoneally [19]. 
The fourth group as well had bile duct ligation then 
was given AM1241 daily in a dose of 3 mg/kg 
dissolved in the vehicle, intraperitoneally [20]. After 
three weeks (at 24 h after the last injection), blood 
samples were collected from the tail vein, and serum 
was separated by centrifugation at 3000 × g for 10 
min and was used for the biochemical assessment. 
Rats were sacrificed by cervical dislocation, and livers 
were dissected, weighed, and liver to body weight 
ratio was calculated.  
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Serum biochemistry of liver 
transaminases, ALP and bilirubin levels 
Serum concentrations of aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), alkaline phosphatase (ALP), total and direct 
bilirubin were determined using colourimetric kits 
(Biodiagnostic, Cairo, Egypt) [21], [22], [23].  
 
ELISA for hepatic MDA, GSH, TNF-α, IL-10 
and hydroxyproline content 
Liver tissues were washed and homogenised 
in ice-cold PBS (pH = 7.4) to obtain a 20% 
homogenate (w·v 1), which was then centrifuged for 
15 min at 3000 x g and 4°C. The supernatant obtained 
was used for measuring MDA (Bioassay co., China), 
GSH (Biotech co., China), TNF-α (Cusabio co., 
China), IL-10 (Cusabio co., China) and hydroxyproline 
(Cusabio co., China) using sandwich ELISA kits 
according to the manufacturer’s instructions. Results 
were expressed for GSH, TNF and IL-10 as pg/mg 
protein while for MDA were expressed as nmol/mg 
and for hydroxyproline as ng/g [24], [25], [26], [27]. 
 
qRT-PCR analysis of α-FP and CD34 gene 
expression 
Total RNA was isolated from rat liver samples 
using the RNeasy Mini Kit (Qiagen, Hilden, Germany). 
Reverse transcription and quantitative real-time PCR 
(qRT-PCR) were performed using SYBR® Premix 
Ex TaqTM (TaKaRa, Biotech. Co. Ltd.). The 
cycling conditions were as follows: reverse 
transcription at 50°C for 30 min, initial denaturation at 
95°C for 10 min, followed by 40 cycles of denaturation 
at 95°C for 15 s, annealing at 55°C for 30 s and 
extension at 72°C for 30 s. The relative mRNA level of 
the target genes was calculated by the comparative 
threshold cycle (Ct) method and was normalised on 
the bases of β-actin expression. The fold change in 
the expression of each target gene was calculated by 
the following formula: relative quantification = 2ΔΔCt. 
The following primer sequences were used: CD34 
forward primer: 5′- AGC CCT ACA GGA GAA AGG 
CTG -3′, CD34 reverse primer: 5′- TCA CAG TTC 
TGT GTC AGC CAC -3′, β-actin forward primer: 5′- 
TTT GCA GCT CCT TCG TTG CC-3′, β-actin reverse 
primer: 5′- CGG TTG GCC TTA GGG TTC AGG GGG 
G-3′, α-FP forward primer: 5′- AGC GAG GAG AAA 
TGG TCC GG -3′, α-FP reverse primer: 5′- GGA CAT 
CTT CAC CAT GTG G -3′ (Metabion, Germany) [28], 
[29]. 
 
Histopathological examination 
Autopsy samples were taken from the liver of 
rats in different groups and fixed in 10% formol saline 
for twenty-four hours. Washing was done in tap water 
then serial dilutions of alcohol (methyl, ethyl and 
absolute ethyl) were used for dehydration. Specimens 
were cleared in xylene and embedded in paraffin at 56 
degrees in a hot air oven for twenty-four hours. 
Paraffin bees wax tissue blocks were prepared for 
sectioning at 4 microns’ thickness by sledge 
microtome. The obtained tissue sections were 
collected on glass slides, deparaffinized, stained by 
hematoxylin &eosin stain as well as Masson 
Trichrome for routine examination through the electric 
light microscope [30]. The severity of histopathological 
alternation was semi-quantitatively assessed based 
on liver histology evaluated by a blinded pathologist 
using a scoring system in which score 0 indicated no 
alternation; score 1, mild alternation; score 2, 
alternation activity; score 3, severe alternation. 
 
Immunohistochemical analysis of α-SMA, 
p53, α-FP and CD34 
Paraffin-embedded liver sections were 
deparaffinized and hydrated. Immunohistochemical 
analyses were performed by a standard streptavidin-
biotin-peroxidase procedure. The paraffin sections 
were heated in a microwave oven (25 min at 720 W) 
for antigen retrieval and incubated with one of the 
following primary antibodies: rabbit polyclonal anti-rat 
p53, rabbit polyclonal anti-rat a-FP, rabbit monoclonal 
anti-rat CD34 and rabbit monoclonal anti-rat α-SMA 
(1:50 dilution; Abcam, Cambridge, MA, USA) and 
incubated overnight at 4°C. After washing with PBS, 
followed by incubation with the corresponding 
biotinylated secondary antibody (1:200 dilutions; Dako 
Corp.) and streptavidin/alkaline phosphatase complex 
(1:200 dilutions; Dako Corp.) for 30 min at room 
temperature, the binding sites of antibody were 
visualised with DAB (Sigma). After washing with PBS, 
the samples were counterstained with H&E for 2–3 
min, and dehydrated by transferring them through 
increasing ethanol solutions (30%, 50%, 70%, 80%, 
95%, and 100% ethanol). Following dehydration, the 
slices were soaked twice in xylene at room 
temperature for 5 min, mounted, examined, and 
evaluated by a high-power light microscope [31].  
 
Quantitative morphometric analysis of 
Masson’s trichrome, α-SMA, p53, α-FP and 
CD34 
Quantitative morphometric analysis for 
Masson’s trichrome, α-SMA, P53, α-FP and CD34 
was performed at the Pathology Department, National 
Research Center by measuring the percentage of the 
positive stained area using the Leica Qwin 500 Image 
Analyzer (LEICA Imaging Systems Ltd, Cambridge, 
England). Morphometric measurements were 
performed on real-time image from the microscope 
that was visualised on the video monitor at high power 
magnification (200 ×). The marker colour to be 
detected was selected, then the software formed a 
binary image for the area of stained by the marker. 
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This area is determined as an area per field in 
micrometre square, area fraction and area percentage 
by using the interactive measurement software of the 
system. The results appeared in the form of mean, 
standard deviation, standard error, the minimum area 
and the maximum area measured. Quantitative image 
analysis for the selected marker was expressed as the 
percentage of stained area averaged across 5 
different fields for each rat of at least six rats [32].  
 
Data and statistical analysis 
The data and statistical analysis in this study 
comply with the recommendations on the 
experimental analysis in pharmacology [33]. Results 
are expressed as mean ± SE. Multiple comparisons 
were performed using two-way ANOVA followed by 
Tukey-Kramer as a post hoc test. P < 0.05 was 
considered statistically significant. All analyses and 
graphs were performed using GraphPad Prism 
software (version 7). 
 
 
Results 
 
AM1241 treatment amended BDL-induced 
hepatic damage 
As compared with the sham group, ALT, AST 
and ALP serum levels were significantly elevated in 
the BDL group. On the other hand, the levels of ALT, 
AST and ALP were significantly less elevated with 
AM1241 treated rats by 21%, 31% and 29% 
respectively, compared to that of the BDL group levels 
but they remained significantly higher than the sham 
values. In line with the cholestatic injury, the BDL 
group also showed a significant rise in total and direct 
bilirubin, compared to the control as they are not 
excreted through the obstructed bile duct and due to 
damaged hepatocytes. However, these values were 
significantly less elevated in AM1241 treated rats by 
19%, 27% respectively than nontreated BDL group; 
moreover, it remained significantly higher than the 
silymarin group. 
Table 1: Effect of AM1241 (3 mg/kg b.wt.) and silymarin (50 
mg/kg b.wt.) treatment for three weeks on hepatotoxicity 
indices, liver and body weight ratio in bile duct ligated (BDL) 
rats 
Groups ALT AST ALP Total 
Bilirubin 
Direct 
Bilirubin 
Change 
in body 
weight 
Liver to 
body 
weight 
ratio 
Sham 22.83 ± 
0.61
bc
 
24.33 ± 
0.92
bc
 
41.67 ± 
0.71
bc
 
0.61 ± 
0.06
bc
 
0.17 ± 
0.014
bc
 
32.5 ± 
8.04
bc
 
0.031 ± 
0.001
bc
 
BDL 82 ± 2.35
ac
 114 ± 2.89
ac
 132.33 ± 
2.47
ac
 
21.81± 
0.90
ac
 
10.58 ± 
0.54
ac
 
-23 ± 9.61
a
 0.065 ± 
0.002
ac
 
BDL + 
Silymar
in 
56 ± 1.34
ab
 66.33 ± 
2.33
ab
 
82.67 ± 
2.23
ab
 
12.23 ± 
1.6
ab
 
6.5 ± 
0.44
ab
 
-17.27 ± 
14.02
a
 
0.056 ± 
0.002
ab
 
BDL + 
AM124
1 
64.83 ± 
2.91
abc
 
78.87 ± 
2.29
abc
 
94 ± 1.63
abc
 17.63 ± 
0.56
abc
 
7.7 ± 
0.51
ab
 
-17.5 ± 
10.01
a
 
0.051 ± 
0.002
ab
 
 
Bile duct ligated rats significantly lost weight 
as compared to sham rats, moreover AM1241 and 
silymarin treated rats also lost weight without a 
difference with BDL group. Regarding liver to weight 
ratio, the increase observed in the BDL group, 
compared to the sham group, was significantly 
reduced by the administration of AM1241 and 
silymarin (Table 1). 
Moreover, liver from bile duct ligated rat liver 
showed a nodular yellow brownish surface with 
oedema formation, distended bile cyst and fatty 
changes. However, treatment with AM1241 and 
silymarin produced a smooth, faint brownish surface 
(Figure 1). 
 
Figure 1: Effect of AM1241 (3 mg/kg) and silymarin (100 mg/kg) 
treatment for three weeks on gross liver morphology in bile duct 
ligated (BDL) rats. Liver from sham rat shows normal brownish 
surface (A), bile duct-ligated rat liver shows a nodular yellow 
brownish surface with oedema formation, distended bile cyst 
(arrow) and fatty changes (B), while liver treated with silymarin 
shows a smooth faint brownish surface with distended bile cyst 
(arrow) (C). Moreover, AM1241 treated rats show similar smooth, 
faint brownish surface (D) 
 
AM1241 treatment inhibited 
histopathological deterioration induced by 
BDL 
H&E stained liver sections obtained from 
sham group revealed no histopathological alteration 
and the normal histological structure of the central 
vein and the portal area with the portal vein, hepatic 
artery and bile ducts were recorded in (Figure 2a and 
2b). However, in bile duct ligated rats, coagulative 
necrosis was observed in some hepatocytes which 
were characterised by deep eosinophilic cytoplasm 
and pyknotic deep blue nuclei in association with 
another dysplastic one with karyocytomegaly (Figure 
2c, 2d and 2e). The hepatic capsule (Glisson's 
Capsule) showed thickening associated with a fatty 
change in the underlying hepatocytes (Figure 2f and 
2g). Massive inflammatory cells infiltration was 
detected in the portal area associated with 
hyperplasia with the atypical epithelium of the bile 
ducts extended to the hepatic parenchyma (Figure 2h 
and 2i). There was neocholangiolar proliferation of the 
bile ducts characterised by hyperplasia and 
hypertrophy with ductular and glandular structure 
presented in between the damage hepatocytes as 
regenerative effects (Figure 2j).  
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Figure 2: AM1241 treatment (3 mg/kg for 3 weeks) alleviated 
histopathological deterioration using H&E staining (×40 & ×80) in hepatic 
fibrosis associated with bile duct ligation (BDL). Liver sections of (a & b) 
sham rats showing the normal histological structure of the central vein 
(cv), surrounding hepatocytes (h) in the parenchyma, and normal portal 
area (pa). (c, d & e) BDL liver tissue is showing coagulative necrosis 
(arrow) with deeply eosinophilic cytoplasm and pyknotic nuclei 
hepatocytes while other dysplastic (d) with disfiguration and cytomegaly 
and karyomegalocytic cells (k). (f & g) BDL liver tissue is showing thick 
capsule (c) with fatty changes (f) in underlying hepatocytes. (h & i) BDL 
liver tissue is showing massive inflammatory cell infiltration (m) in the 
portal area with hyperplastic bile duct cells resembling hepatocytes, 
biliary epithelium and extending to the parenchyma (bd). (j) BDL liver 
tissue is showing hyperplasia and hypertrophy (hp) with ductular 
glandular structure presented in freshly damage liver cells as a 
regenerative effect (neocholangiolar proliferation). (k) BDL liver tissue is 
showing oval or spindle cell (arrow) basophilic extended in between the 
hyperplastic hypertrophic bile ducts in the hepatic parenchyma. (l) 
silymarin treated liver tissue showing dilated portal vein (pv) with 
lobulation of the hepatocytes (hl) with multiple proliferated oval or 
spindle cells (arrow) and dysplasia (ds) in the other with prominent 
nucleoli. (m) silymarin treated liver tissue showing increase proliferation 
of the bile ducts (bd), hypertrophic biliary epithelium, atypia and 
inflammatory cell infiltrate (m) in portal area. (n & o) silymarin treated 
liver tissue showing coagulative necrosis in some of the hepatocytes, 
dysplasia in other with enlarged spindle cells extended in between in the 
parenchyma. (p) AM1241 treated liver tissue showing thickening (c) with 
inflammatory cells infiltration (m) in the hepatic capsule with dysplasia 
(ds) in the underlying hepatocytes and atrophy in other. (q) AM1241 
treated liver tissue showing oval cells proliferation (o) in between the 
dysplastic hepatocytes (arrow). (r) AM1241 treated liver tissue showing 
inflammatory cells infiltration (m) with few fibroblastic cells proliferation in 
the portal area (arrow). (s) AM1241 treated liver tissue showing focal 
loss of cell detail and architecture as necrosis (ne) surrounded by 
fibrosis (f) and oval cells (o) 
 
Oval or basophilic spindle cells were 
extended in between the hyperplastic hypertrophied 
ducts in the parenchyma (Figure 2k). In silymarin 
treated rats, hepatic capsule showed thickening with 
inflammatory cells infiltration while the underlying 
parenchyma had dysplasia and atrophy (Fig. 2p). 
There was oval cells proliferation in between the 
dysplastic hepatocytes (Figure 2q). Inflammatory cells 
infiltration with few fibroblastic cells proliferation was 
detected in the portal area (Figure 3r). Focal necrosis 
with fibrosis in the surrounding was detected in the 
hepatic parenchyma (Figure 2s). Rat treated with 
AM1241 showed dilatation was observed in the portal 
vein associated with the proliferation of the oval or 
spindles cells which were separated the dysplastic 
with prominent nucleoli hepatocytes into lobules 
(Figure 2l). There was an increase in the bile ducts 
proliferation with hypertrophic biliary epithelium, atypia 
and inflammatory cells infiltration (Figure 2m). 
Coagulative necrosis was detected in some of the 
hepatocytes associated with dysplasia in others as 
well as an extension of spindle cells proliferation in 
between (Figure 2n & 2o). Table 2 summarise the 
histopathological alterations demonstrated in liver 
tissue of BDL rats. 
Table 2: Effect of administration of AM1241 (3 mg/kg b.wt.) and 
silymarin (50 mg/kg b.wt.) for three weeks on histopathological 
alternations of hepatic tissue in bile duct ligated (BDL) rats 
 
 
Groups 
 
Hepatic 
capsule  
thickenin
g 
 
Degeneration 
and necrosis 
of hepatic 
parenchyma 
 
Dysplasia 
of 
hepatocyte 
Hyperplasia, 
hypertrophy 
and  
neocholangiol
ar formation 
with atypia, 
cytomegaly 
 
Portal 
inflammatory 
reaction 
 
Oval cell 
proliferation 
 
Fibrosis 
Sham 0 0 0 0 0 0 0 
BDL 1 3 3 3 3 2 2 
BDL + 
Silymarin 
2 2 2 2 2 2 2 
BDL + 
AM1241 
0 2 2 2 1 3 1 
 
 
AM1241 treatment mitigated BDL-induced 
hepatic fibrogenesis 
ELISA analysis showed that that bile duct 
ligation caused a significant rise in hepatic 
hydroxyproline levels (up to 3 folds), compared to that 
of the control group. However, silymarin group didn’t 
show significant difference with BDL rats, AM1241 
treatment successfully reduced the elevation of 
hydroxyproline levels, compared to that of the BDL 
group (Table 3).  
Table 3: AM1241 treatment (3 mg/kg for 3 weeks) alleviated 
hepatic fibrogenesis in bile duct ligated (BDL) rats 
Groups HP MT % SMA % 
Sham 1.03 ± 0.06
bc
 17.12 ± 1.88
bc
 7.11 ± 1.29
bc
 
BDL 4.09 ± 0.09
a
 39.76 ± 2.10
a
 39.03 ± 2.30
ac
 
BDL + Silymarin 4.02 ± 0.20
a
 32.61 ± 2.12
a
 16.55 ± 1.98
ab
 
BDL + AM1241 3.29 ± 0.31
ab
 30.04 ± 2.25
ab
 14.30 ± 1.29
ab
 
 
These results matched those obtained from 
histomorphometric measurements of Masson 
Trichrome staining. It was clear that only traces of 
connective tissue elements were present in normal 
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hepatic tissues (Figure 3a), while bile duct ligation 
increased markedly the fibrous components 
associated with portal fibrosis (Figure 3b). Treatment 
of bile duct ligated rats with silymarin produced a less 
significant reduction of fibrosis than that of AM1241 
group (Figure 3c and 3d). However, treatment with 
AM1241 significantly decreased fibrosis by 24% 
compared to the nontreated BDL group (Figure 3e, 3f 
and 3g). 
 
Figure 3: Masson’s trichrome staining of rat liver sections (×40 & 
×80). Sham liver tissue shows traces of connective tissue (blue) in 
the normal hepatic tissue present mainly around the main blood 
vessels (a). Bile duct-ligated rat liver tissue shows massive fibrosis 
in liver tissue with thick fibrous tissue expanded along the portal 
tract and extended into the periportal region. Lost normal 
architecture and dilated bile ducts was also observed (b). Moreover, 
the liver treated with silymarin shows also marked decrease in 
connective tissue (c & d). However, liver treated with AM1241 
shows only a few blue stained collagen bundles surrounding 
hepatic nodules (e, f & g) 
 
Moreover, quantitative morphometric 
investigation of liver sections immunostained with α-
SMA, a marker of fibroblastic cells, i.e. activated 
hepatic stellate cells and portal myofibroblasts 
revealed that only traces of α-SMA expression was 
present in normal hepatic tissues (Figure 4a). In 
contrast, bile duct ligation produced the highest 
expression of α-SMA in hepatic tissue (Figure 4b and 
4c). Treatment with silymarin produced a similar 
insignificant effect to that of AM1241 treated rats 
(Figure 4d). However, treatment with AM1241 
significantly decreased α-SMA expression by 63%, 
compared to that of the nontreated BDL group (Figure 
4e and 4f).  
 
Figure 4: Immunohistochemical detection of α-SMA (×40 & ×80). 
Sham group shows a negligible positive reaction (a), bile duct 
ligated group shows highest reaction (b & c), group treated with 
silymarin shows decrease in reaction (d), while AM1241 treated 
group shows a more noticeable decrease in reaction (e & f) 
AM1241 treatment attenuated BDL-induced 
oxidative stress 
The effect of AM1241 on oxidative stress was 
investigated by measuring hepatic levels of the lipid 
peroxidation end-product (MDA; malondialdehyde) 
and the antioxidant molecule (GSH). GSH levels were 
markedly reduced while levels of lipid peroxides were 
significantly elevated in the BDL group, compared to 
that of the control group. Interestingly, Treatment with 
AM1241 significantly prevented the elevation of MDA 
by 45% and restored GSH levels up to 5 more folds 
than the nontreated BDL group (Table 4). Moreover, 
AM1241 exhibited a superior effect when compared to 
that of silymarin treated group. 
Table 4: Effect of administration of AM1241 (3 mg/kg b. wt.) and 
silymarin (50 mg/kg b. wt.)  for three weeks on tissue oxidative 
stress markers in bile duct ligated (BDL) rats 
Groups MDA 
(nmol/mg) 
GSH 
(pg/mg) 
Sham 31.67 ± 1.09
bc
 122.67 ± 2.45
bc
 
BDL 182.167 ± 6.41
ac
 14.87 ± 0.89
ac
 
BDL + Silymarin 134.67 ± 3.99
ab
 70.57 ± 3.94
ab
 
BDL + AM1241 99 ± 3.02
abc
 89.8 ± 2.89
abc
 
 
 
AM1241 treatment alleviated BDL-induced 
hepatic inflammation 
The anti-inflammatory potential of AM1241 
was determined by measuring levels of the pro-
inflammatory cytokine (TNF-α) and the anti-
inflammatory marker (IL-10). As shown in Table 3, the 
marked rise in serum TNF-α levels observed in the 
BDL group was significantly decreased (33%) by 
AM1241 treatment. Silymarin produced a more 
significant decrease in TNF-α levels, compared to that 
of AM1241 group. 
Regarding IL-10 serum levels, bile duct 
ligated rats showed a significant decrease, compared 
to the control group, whereas treatment with AM1241 
markedly restored these levels up to 5.6 more folds 
than the nontreated BDL group. Further, treatment 
with silymarin showed a significant inferior effect when 
compared to AM1241 group (Table 5). 
Table 5: Effect of administration of AM1241 (3 mg/kg b.wt.) and 
silymarin (50 mg/kg b.wt.)  for three weeks on tissue 
inflammatory response in bile duct ligated (BDL) rats 
Groups TNF-α 
(pg/mg) 
IL-10 
(pg/mg) 
Sham 37.27 ± 1.28
bc
 124.37 ± 1.78
bc
 
BDL 223.53 ± 3.75
ac
 14.43 ± 0.85
ac
 
BDL + Silymarin 130.8 ± 6.15
ab
 66.2 ± 3.82
ab
 
BDL + AM1241 149.2 ± 4.48
abc
 95.83 ± 2.18
abc
 
 
 
AM1241 treatment alleviated p53-
dependent hepatocyte apoptosis 
Table 6 summarizes the quantitative 
morphometric investigation of liver sections 
immunostained with p53 of BDL rats. Liver sections of 
normal hepatic tissues showed a negligible positive 
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reaction of p53 expression (Figure 5a). Bile duct 
ligation produced a large increase in p53 
immunoreactivity (Figure 5b and 5c).  
Table 6: AM1241 treatment (3 mg/kg for 3 weeks) alleviated 
hepatic fibrogenesis in bile duct ligated (BDL) rats 
Groups P53 
Sham 5.53 ± 0.53
bc
 
BDL 32.77 ± 2.44
ac
 
BDL + Silymarin 23.85 ± 1.84
ab
 
BDL + AM1241 15.89 ± 1.89
abc
 
 
Silymarin treatment was less effective in 
reducing p53 induction (Figure 5d), and treatment with 
AM1241 significantly decreased p53 expression 
significantly by 51%, compared to that of the 
nontreated BDL group (Figure 5e).  
 
Figure 5: Immunohistochemical detection of p53 (×40 & ×80). Sham 
group shows a negligible positive reaction (a), bile duct ligated 
group shows highest reaction (b & c), group treated with silymarin 
shows decrease in reaction (d), while AM1241 treated group shows 
a more noticeable decrease in reaction (e) 
 
AM1241 treatment augmented liver 
regeneration by activating hepatic 
progenitor cell proliferation  
The effect of AM1241 on liver regeneration 
through activation of hepatic progenitor cells 
proliferation was determined by measuring levels of its 
surface markers, CD34 and α-FP. qRT-PCR analysis 
of CD34 and α-FP mRNA expression in the bile duct 
ligated group showed no significant changes from the 
control group. Silymarin treatment didn’t show any 
significant effect over the nontreated BDL rats. 
Strikingly, treatment with AM1241 significantly up-
regulated the genetic expression of CD34 and α-FP 
(252% and 89% respectively), compared to that of the 
nontreated BDL group (Table 7). 
Table 7: AM1241 treatment (3 mg/kg for 3 weeks) augmented 
hepatic progenitor cell expression in bile duct ligated (BDL) 
rats 
Groups AFP % AFP PCR CD34 % CD34 PCR 
Sham 14.904 ± 3.32
bc
 0.39 ± 0.04
bc
 3.70 ± 0.81
bc
 1.14 ± 0.11 
BDL 34.30 ± 3.09
a
 0.83 ± 0.03
a
 17.55 ± 2.15
a
 2.32 ± 0.43 
BDL + 
Silymarin 
41.69 ± 2.50
a
 0.755 ± 0.036
a
 23.59 ± 2.66
a
 2.20 ± 0.49 
BDL + 
AM1241 
55.03 ± 2.23
abc
 1.57 ± 0.07
abc
 38.18 ± 1.91
abc
 8.17 ± 1.021
abc
 
 
Histomorphometric measurement for CD34 
and α-FP immunostained liver sections demonstrated 
a very similar pattern as the qRT-PCR measurements. 
Only traces of CD34 and α-FP were found in normal 
hepatic tissues (Figure 6a, 6b and 7a). Bile duct 
ligated treated rats showed mild expression of CD34 
(Figure 6c, 6d, 7b and 7c). Moreover, silymarin 
treated rats showed also a mild expression of when 
stained with CD34 (Figure 7d and 7e).  
 
Figure 6: Immunohistochemical detection of α-FP (×40 & ×80). 
Sham group shows the negligible positive reaction of this stain (a & 
b), a noticeable increase in the reaction in BDL group (c & d) and 
silymarin treated group (e & f) and highest reaction in AM1241 
treated group (g & h) 
 
However, it revealed more significant 
expression when stained with α-FP (Figure 6e and 6f). 
Treatment with AM1241 showed the highest 
expression of CD34 and α-FP (117% and 60% 
respectively, compared to BDL group) with observed 
oval hepatic progenitor cells (Figure 6g, 6h, 7f, 7g). 
 
Figure 7: Immunohistochemical detection of CD34 (×40 & ×80). 
Sham group shows no positive reaction (a), mild increase in the 
reaction in both BDL (b & c) and silymarin groups treated groups (d 
& e) and highest reaction in the group treated with AM1241 (f & g). 
Notice the hepatic progenitor cells is well expressed in AM1241 
treated group 
 
 
Discussion 
 
The current study reports the potential 
antifibrotic mechanisms of CB2 receptors activation 
through studying the key events involved in hepatic 
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fibrosis such as oxidative stress, inflammation and 
apoptosis. This study is the first to investigate the 
potential effect of CB2 receptor on liver regeneration 
associated with hepatic progenitor cells stimulation. 
These effects largely depend on its direct impact on 
CB2-expressing hepatic immune cells and hepatic 
myofibroblasts and its indirect effect on hepatocytes, 
which do not express CB2 [8], [34]. 
BDL is the classic experimental model for 
induction of cholestatic liver fibrosis in rodents. In our 
study following 3 weeks of bile duct ligation, there was 
a marked decrease in body weight associated with an 
increase in liver weight. Reduced body weight could 
be attributed to reduced intestinal bile secretion and 
food absorption while increased liver weight is 
referred to as hepatic congestion and swelling [35]. 
AM1241 treatment significantly attenuated body 
weight loss and liver weight increase. 
Biliary obstruction causes an irregular flux of 
bilirubin and bile acids in the liver. Toxic hydrophobic 
bile salts subsequently accumulate within hepatocytes 
causing progressive hepatocellular necrosis and 
apoptosis via free radical generation. Early studies 
using rodent hepatocytes assumed that cholestatic 
liver injury is mainly caused by direct toxicity of 
hydrophobic bile acids, which induce mitochondrial 
oxidative stress and apoptosis [36]. However, the 
predominant bile acids in rodents are not cytotoxic; 
they promote inflammatory gene expression which is 
responsible for hepatic neutrophil recruitment and an 
inflammatory injury. Neutrophil cytotoxicity involves 
extensive neutrophil-derived oxidative stress and 
hepatocyte necrosis [37]. This was reflected in the 
present study by the elevation in serum 
transaminases, ALP and bilirubin in the BDL group. 
Moreover, Histopathological examination 
revealed coagulative necrosis in association with 
many dysplastic cells and hepatocytes showing fatty 
changes. Massive inflammatory cells infiltration was 
detected in the portal area associated with the neo-
cholangiolar proliferation of the bile ducts as 
regenerative effects. Oval basophilic cells were 
extended in between the hyperplastic ducts. Daily 
administration of AM1241 produced significant 
decrease in serum transaminases, ALP and bilirubin 
levels with no significant difference from silymarin 
group. However, histopathological examination still 
reveals areas of coagulative necrosis in some of the 
hepatocytes associated with few dysplastic cells as 
well as proliferation of oval cells in between. Moderate 
Inflammatory cells infiltration with few fibroblastic cells 
proliferation was detected in the portal area. These 
results confirm the previous findings by Batkai, Osei-
Hyiaman [9] who reported that administration of CB2 
agonist, JWH-133 protected against hepatic I/R 
(ischemia reperfusion) injury whereas, CB2 deficient 
mice displayed enhanced liver injury and inflammation 
following I/R. The reported mechanism involved 
decreased inflammatory cell infiltration, reduced lipid 
peroxidation and expression of pro-inflammatory 
cytokines. Moreover, Batkai, Osei-Hyiaman [9] 
experiments in cultured sinusoidal endothelial cells 
indicated that CB2 activation reduced tumor necrosis 
factor alpha-induced adhesion molecules with 
decreased adhesion of neutrophils to endothelial cells.  
Liver fibrosis of any aetiology is characterized 
by progressive accumulation of collagenous fibrous 
tissue in the liver parenchyma with the proliferation of 
collagenous secreting activated hepatic stellate cells 
(HSCs) and portal myofibroblasts [38]. In this context, 
BDL in our study produced marked collagenous 
filaments deposition around portal tract as indicated 
by Masson’s trichrome stained fibrous bands, 
increased liver hydroxyproline content (a marker of 
collagen deposition) and also by increased α-SMA 
expression (a marker of HSCs). The present study 
demonstrates that CB2 activation successfully 
decreased BDL-induced fibrogenesis. This was 
concluded by the significant reduction in liver 
hydroxyproline levels, measured with ELISA and the 
decrease of collagen deposition, measured with 
morphometric analysis of Masson’s stain. This also 
was coincided with a significant reduction in α-SMA 
expression. These results confirm the previous 
findings by Julien, Grenard [6] who reported that CB2 
knockout mice showed a diminished cirrhosis when 
exposed to CCl4, as assessed by morphometric 
analysis of Sirius red-stained slides, and by 
measurement of collagenous protein 
spectrophotometrically, whereas Munoz-Luque, Ros 
[39] reported that administration of the CB2 agonist 
JWH-133 to CCl4 rats improved liver fibrosis, 
decreases the inflammatory infiltrate and reduces the 
density of hepatic myofibroblasts. 
Moreover, Julien et al., 2005 also reported 
that activation of CB2 receptors in cultured activated 
hepatic stellate cells reduced cell accumulation and 
triggered its apoptosis by stimulating both COX-2 and 
oxidative stress. They reported that THC increased 
COX-2 protein expression and ROS activity that 
induced HSCs apoptosis. However, the apoptosis was 
diminished by selective COX-2 inhibitor and two 
potent antioxidants, respectively. 
CB2 receptors expressed on hepatic 
inflammatory cells play a major role in amelioration of 
hepatic injury and fibrogenesis. Previous literature 
showed that CB2 agonists prevented the switch of 
Kupffer cells to a pro-inflammatory M1 phenotype, and 
enhances transition towards the anti-inflammatory M2 
phenotype, via a mechanism involving activation of 
heme oxygenase-1 [40]. While others reported that 
CB2 receptors activation downregulated the 
production of the profibrogenic cytokine IL17 by Th17 
lymphocytes [41], [42]. Moreover, our finding showed 
that CB2 receptors produced a marked elevation of 
immunoregulatory IL-10 as compared to both BDL 
and silymarin groups. IL-10 produced by M2b 
macrophages and Th2 lymphocytes is a potent 
stimulator of HO-1 with subsequent enhancing 
polarisation of macrophages toward 
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immunoregulatory M2c phenotype [43], [44], [45]. 
Also, IL-10 produces apoptosis of pathogenic Th17 
and decreases the release of inflammatory IL-17 [46], 
[47], [48]. This was evident in our experiment by a 
significant decrease of TNF-a, a marker of pro-
inflammatory M1-macrophages and by a significant 
increase of IL-10, a marker of anti-inflammatory M2-
macrophages. 
Neutrophil accumulation in the liver is a 
common feature of the cholestatic liver disease and is 
mediated by several adhesion molecules and 
inflammatory cytokines released from kupffer cells. 
These inflammatory cells attach to hepatocytes and 
release ROS and other oxidants. These changes, in 
turn, trigger intracellular oxidative stress and lipid 
peroxidation inside the hepatocytes [49], [50]. This 
was evident in the present study by the remarkable 
increase in lipid peroxidation expressed as MDA 
content and the depletion of GSH levels. Oxidative 
stress is found to play a major role in the 
pathogenesis of cholestasis as it induces hepatocyte 
death (both apoptotic and necrotic), amplifies the 
inflammatory response. Treatment of BDL rats with 
CB2 agonist in the present study effectively reduced 
the lipid peroxidation and restored the hepatic 
antioxidant defence system as shown by the marked 
improvement of MDA and GSH activity which was 
coincided with a decreased number of inflammatory 
cells as shown by H&E stain, compared to both BDL 
and silymarin groups. This goes in line with previous 
studies which reported that activation of CB2 
receptors by JWH133 and cannabidiol decreased 
hepatic ROS and lipid peroxidation end-products by 
attenuating neutrophil infiltration and expression of 
neutrophil adhesion molecules in an animal model of 
I/R and alcohol-induced injury, respectively [9], [51]. 
Moreover, CB2 receptors were reported to 
play a role in reducing oxidative stress markers in 
hydrogen peroxide stimulated cultured RAW 264.7.7 
macrophages [52]. 
p53 is an oncoprotein, potentially stimulate 
cell growth arrest and apoptosis and is upregulated in 
many liver diseases, ranging from fatty liver disease to 
HCC [53]. p53-dependent mitochondrial stress is 
found to induce apoptosis associated with increased 
Bax and Bcl2 in bile acid-induced liver toxicity in both 
in-vivo and in-vitro [54], [55]. It is also associated with 
increased lipid peroxidation and mitochondrial stress 
in CCL4 rats [56], [57], [58]. Likely, BDL in the present 
study showed a marked increase in the apoptotic 
process with strong cytoplasmic immunoreactions for 
p53. However, daily treatment with AM1241 produced 
a significant reduction in expression of p53 as 
compared to both BDL and silymarin groups. Previous 
studies also reported that 2-AG-mediated CB2 
signalling by MAGL inhibition protects against 
hepatocyte apoptosis elicited by acute liver injury [59]. 
However, CB2 receptors are not expressed inside the 
hepatocytes, their impact on modulation of the 
proinflammatory cytokines and oxidative stress may 
explain an indirect and paracrine effect on hepatocyte 
apoptosis. 
A heated debate raged for years as regard to 
the role of oval/progenitor cells in liver regeneration 
which is capable of generating both hepatocytes and 
biliary cells following BDL [60], [61], [62]. Our results 
showed that sham rats showed negative expression of 
CD34 and α-FP by immunostaining and gene 
expression with no detection of oval cells by H&E. 
However, BDL and silymarin groups showed 
moderate expression of these oval cell markers and 
its gene expression with observed oval cells by H&E. 
Interestingly, treatment with AM1241 produced a 
significant expression of α-FP and CD34 
immunoreaction and enhanced its gene expression 
with more detected oval cells by H&E as compared to 
both BDL and silymarin group. Moreover, certain bile 
acids and growth factors were found to be a potent 
stimulator of progenitor profile of mesenchymal cells 
[63] where others reported that kupffer cells 
modulation initiate oval cells stimulation [64]. Whether 
CB2-dependent modulation of kupffer cells activity 
and growth factors plays a role in progenitor cells 
stimulation would be further investigated. Moreover, 
CB2 receptors were previously reported to promote 
neural and cardiac progenitor cells regeneration. 
Palazuelos, Aguado [65] reported that stimulation of 
CB2 receptors enhanced the proliferation of neural 
progenitor cells, both in vitro and in vivo while Wang, 
Ma [66] reported that AM1241 promoted proliferation 
of ki-67 immunostained cardiac progenitor cells 
(CPCs) and encouraged cardiomyocyte regeneration 
in post-myocardial infarction.  
In conclusion, our data demonstrate that CB2 
receptors reduce liver injury and fibrogenesis following 
bile duct ligation with explaining new distinct 
mechanisms originating from hepatic myofibroblasts 
and immune cells. These include IL-10 dependent 
inhibition of inflammatory mediators, reduction of lipid 
peroxidation inside hepatic cells and inhibition of 
hepatocyte p53-dependent apoptosis. Besides, CB2 
receptors are shown to possess a regenerative effect 
through stimulation of HPCs stimulation. These results 
suggest that CB2 agonists display potent 
hepatoregenrative properties, in addition to their 
antifibrogenic effects. 
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